drugset

drugset / Trial / NCT03845179

GA 6: The Blood Glucose-lowering Effect of Glucose-dependent Insulinotropic Polypeptide

NCT03845179 ↗

Completed 12 enrolled University Hospital, Gentofte, Copenhagen

RandomizedCrossoverDouble-blindBasic science

Summary

This study will investigate if the effect of DPP-4 inhibitors is mediated in part by Glucose-dependent insulinotropic polypeptide.

Timeline

Start: 2019-05-29
Primary completion: 2020-02-28
Completion: 2020-02-28

Publications

Stensen S, Gasbjerg LS, Rosenkilde MM, Vilsboll T, Holst JJ, Hartmann B, Christensen MB, Knop FK. Endogenous Glucose-Dependent Insulinotropic Polypeptide Contributes to Sitagliptin-Mediated Improvement in beta-Cell Function in Patients With Type 2 Diabetes. Diabetes. 2022 Oct 1;71(10):2209-2221. doi: 10.2337/db22-0059.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Sitagliptin	Small molecule	100 mg	Oral

Indications